Skip to content
MYGN·Nasdaq·US

Myriad Genetics

Myriad Genetics is a molecular diagnostics company that develops and commercializes genetic and genomic tests for cancer risk, oncology decision support, and pharmacogenomics. It generates revenue primarily from proprietary laboratory-based testing sold to clinicians and health systems.

Recent Activity

Updated Oct 24, 2026
–Myriad Genetics and Labcorp announced a definitive agreement under which Myriad will sell its prenatal health testing business to Labcorp.

Past updates are part of the Pro plan.

Thematic Position

MYGN

Relationship Groups

Partners2
Licensing1
Competitors10

Relationship details are part of the Pro plan.

Ended Relationships

1 ended relationship · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

regulatory enforcementFalse Claims Actfederal investigation
U.S. DOJ False Claims Act investigation into Myriad Genetics physician referral payments
SEC 10-QJul 31, 2026

The full regulatory passage is part of the Pro plan.

14 more · Regulatory and geopolitical insights are part of the Pro plan.